Nonlipid-lowering effects of statins
- 79 Downloads
Statins have been shown to effectively reduce cardiovascular events in patients with hypercholesterolemia, diabetes, and coronary disease, and after an acute coronary syndrome in several large-scale clinical trials. Interestingly, numerous studies have suggested that statins exert potentially important effects independent of lipid lowering (ie, improve endothelial function, reduce oxidant stress), and have direct antiinflammatory, antithrombotic, and plaque-stabilizing effects. These beneficial effects may contribute to cardiovascular protection by statin therapy beyond low-density lipoprotein (LDL) cholesterol lowering. Therefore, it remains unclear at present to what extent the beneficial cardiovascular effects of statin treatment are dependent on LDL cholesterol lowering (ie, whether the same effect would be achieved by other modes of lipid lowering). Consequently, statins should be used as a first-line therapy for lipid lowering. Importantly, the observation of LDL cholesterol-independent effects of statins has stimulated clinical studies testing a wider use of statin treatment for diseases that are not thought to be related to increased LDL cholesterol levels, such as in patients with chronic heart failure (in particular dilated cardiomyopathy) and even in inflammatory diseases such as rheumatoid arthritis and multiple sclerosis.
KeywordsStatin Acute Coronary Syndrome Simvastatin Chronic Heart Failure Endothelial Function
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 3.Loscalzop J: Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001, 88:756–762.Google Scholar
- 5.Laufs U, La Fata V, Plutzky J, et al.: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 12:1129–1135.Google Scholar
- 8.Landmesser U, Engberding N, Bahlmann FH, et al.: Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004, 110:1933–1939.PubMedCrossRefGoogle Scholar
- 10.Wassmann S, Faul A, Hennen B, et al.: Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003, 93:e98-e103. Demonstrates that a single oral 40-mg dose of pravastatin significantly attenuated coronary endothelial dysfunction in patients with coronary disease without any effects on serum cholesterol levels, suggesting a direct LDL cholesterol-independent effect of statin treatment on endothelial function.PubMedCrossRefGoogle Scholar
- 11.Landmesser U, Bahlmann F, Mueller M, et al.: Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005, 111:2356–2363. Compares the effect of 4 weeks of treatment with simvastatin or ezetimibe, dosed to achieve a similar reduction of LDL cholesterol levels, on endothelial function in patients with CHF. Statin treatment but not ezetimibe therapy improved endothelial function, strongly suggesting that prolonged statin therapy exerts beneficial effects on endothelial function independent of lipid lowering. This may help to explain beneficial effects of statins in patients with CHF independent of LDL cholesterol.PubMedCrossRefGoogle Scholar
- 23.Maack C, Kartes T, Kilter H, et al.: Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003, 108:1567–1574. Provides important evidence indicating inhibition of small g protein and oxidant stress in patients with ischemic and dilated cardiomyopathy on statin treatment. These findings may help to explain beneficial effects of statins independent of LDL cholesterol in patients with heart failure.PubMedCrossRefGoogle Scholar
- 32.Kwak B, Mulhaupt F, Myit S, et al.: Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6:1399–1402. Suggests immunomodulation by statin treatment may help to explain the reduced rejection observed in heart transplant patients who received statin therapy.PubMedCrossRefGoogle Scholar